BioMarin Pharmaceutical Inc. develops and commercializes medicines for rare genetic diseases, with recurring news centered on commercial portfolio performance, regulatory approvals, clinical data and business development. Company updates commonly reference therapies for achondroplasia, phenylketonuria, hemophilia, mucopolysaccharidosis and lysosomal storage diseases, including VOXZOGO, PALYNZIQ, GALAFOLD and POMBILITI + OPFOLDA.
BioMarin news also covers financial results, guidance, acquisition integration, debt financing and governance changes. Clinical and regulatory announcements focus on genetically defined conditions, skeletal disorders, enzyme-based therapies and investigational rare-disease programs such as DMX-200 for focal segmental glomerulosclerosis.
BioMarin (NASDAQ: BMRN) priced an $850 million offering of 5.500% senior unsecured notes due 2034 at 100% with expected close on February 12, 2026, and completed syndication of a $2.0 billion Term Loan B facility.
The company also has a $800 million Term Loan A and expects a $600 million revolver; proceeds and borrowings will fund the pending acquisition of Amicus and related fees. Notes proceeds will be held in escrow and must be redeemed if the acquisition is not completed by December 19, 2026.
BioMarin (NASDAQ: BMRN) announced a proposed private offering of $850 million senior unsecured notes due 2034 and launched syndication for a new $2.0 billion senior secured Term Loan B facility, in addition to an $800 million Term Loan A facility and a $600 million senior secured revolving facility to support its pending acquisition of Amicus.
Net proceeds from the notes, borrowings under the new senior secured credit facilities and cash on hand are intended to fund acquisition consideration, fees and expenses. Gross note proceeds will be placed in escrow and must be redeemed if the acquisition is not completed on or prior to December 19, 2026 (subject to specified events). The notes will be guaranteed by certain subsidiaries and will include customary covenants and transfer restrictions.
BioMarin (NASDAQ: BMRN) appointed Arpit Davé as Executive Vice President, Chief Digital and Information Officer, effective Jan 12, 2026. Mr. Davé will report to CEO Alexander Hardy and join the BioMarin Leadership Team.
He will lead enterprise technology strategy, data science and digital transformation to support R&D, manufacturing and commercial operations. Mr. Davé brings more than 20 years of IT and AI experience in biopharma, including 7.5 years as a technology executive at Amgen and prior leadership roles at Bristol Myers Squibb and Merck. He holds an M.S. in Industrial Engineering from the University of Texas and a B.S. in Mechanical Engineering from S.P. University.
BioMarin (NASDAQ: BMRN) announced that Alexander Hardy, President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 11:15 am PT / 2:15 pm ET in San Francisco.
The company plans to announce certain preliminary financial results for the year ended December 31, 2025 during the presentation. An audio webcast will be available live and an archived version will be posted on the company's investor website for a limited time.
BioMarin (NASDAQ: BMRN) and Veeva Systems (NYSE: VEEV) announced a long-term enterprise agreement on January 8, 2026 to expand their existing relationship.
The partnership aims to increase speed, agility and operational efficiency in developing and commercializing therapies by further leveraging and providing strategic input into Veeva's software, data, services, and consulting products, and to optimize the healthcare professional and patient experience. Company leaders highlighted the collaboration's role in accelerating access to transformative medicines globally.
BioMarin (Nasdaq: BMRN) agreed to acquire Amicus Therapeutics for $14.50 per share, valuing the deal at approximately $4.8 billion. The transaction, approved by both boards, is expected to close in Q2 2026 subject to customary approvals. The deal adds marketed therapies Galafold and Pombiliti + Opfolda that generated $599 million in net product revenue over the past four quarters and resolves U.S. Galafold patent litigation with U.S. exclusivity expected through Jan 2037. BioMarin expects the acquisition to be accretive to Non-GAAP diluted EPS within 12 months and substantially accretive in 2027 and plans to finance with cash plus about $3.7 billion of debt.
BioMarin (NASDAQ: BMRN) said its management team will present at the Jefferies Global Healthcare Conference on Tuesday, November 18, 2025 at 10:30 AM GMT in London, England. An audio webcast will be available live and an archived version of the remarks will be posted on the company investor website for a limited time.
Investors can access the live webcast and archive at https://investors.biomarin.com/.
BioMarin (Nasdaq: BMRN) announced the FDA has accepted for Priority Review its supplemental biologics license application to expand PALYNZIQ (pegvaliase-pqpz) for adolescents aged 12–17 with phenylketonuria (PKU).
The sBLA is based on positive Phase 3 PEGASUS results showing statistically significant reductions in blood phenylalanine (Phe) versus diet alone. The FDA set a PDUFA target action date of Feb. 28, 2026. Data were presented at the 15th ICIEM in Kyoto, and BioMarin plans to seek a similar label expansion with the European Medicines Agency. PALYNZIQ is currently the first and only enzyme substitution therapy approved for adults with PKU.
BioMarin (NASDAQ: BMRN) reported Q3 2025 results and a corporate update on October 27, 2025. Total revenues were $776M (+4% vs Q3 2024) and YTD revenues reached $2,347M (+11% Y/Y). Year-to-date VOXZOGO revenue rose 24% Y/Y and Q3 VOXZOGO sales were $218M; PALYNZIQ grew 20% in Q3. GAAP net loss was $(31)M in Q3, driven primarily by a $221M acquired IPR&D charge from the Inozyme acquisition. Non-GAAP income fell to $22M in Q3 from $178M a year earlier. Cash and investments were about $1.99B and operating cash flow was $369M in Q3 ($728M YTD). The company reaffirmed VOXZOGO full-year guidance ($900M–$935M) and updated 2025 guidance, raising mid-point revenue while lowering Non-GAAP EPS and margin guidance to reflect the IPR&D charge. BioMarin plans to pursue options to divest ROCTAVIAN.
BioMarin (NASDAQ: BMRN) announced a conference call and webcast with Alexander Hardy, president and CEO, on Monday, October 27, 2025 at 4:30 p.m. ET to discuss third quarter 2025 financial results and provide a general business update.
Dial-in numbers are provided for U.S./Canada and international participants, and a live audio webcast will be available via the investor site at https://investors.biomarin.com/. A replay will be archived on the site for one week following the call.